Results 121 to 130 of about 768 (176)

Should we stay or should we go? Recent insights on drug discontinuation in multiple sclerosis. [PDF]

Neurol Res Pract
Mrochen A, Meuth SG, Pfeuffer S.
europepmc   +1 more source

Primary Progressive Multiple Sclerosis-A Key to Understanding and Managing Disease Progression. [PDF]

Int J Mol Sci
Sempik I, Dziadkowiak E, Moreira H, Zimny A, Pokryszko-Dragan A.   +4 more
europepmc   +1 more source

Clinical and analytical monitoring of patients with multiple sclerosis on anti-CD20 therapeutics: a real-world safety profile study. [PDF]

Front Neurol
Fernandes AA, Neves AL, Ferro D, Seabra M, Mendonça T, Dos Reis RS, Sá MJ, Guimarães J, Abreu P.   +8 more
europepmc   +1 more source

Treatment Effects on Chronic Active Lesions in Multiple Sclerosis: Current Evidence and Future Perspectives. [PDF]

Neurol Ther
Preziosa P, Guido G, Filippi M, Rocca MA.   +3 more
europepmc   +1 more source

First Reported Case of Ocrelizumab-Associated Leukocytoclastic Vasculitis in Primary Progressive Multiple Sclerosis: A Case Report. [PDF]

Case Rep Neurol
Nahayati M, Farahnezhad M, Khanmirzaei A, Khosravani F.   +3 more
europepmc   +1 more source

Aggressive treatment of early acute focal inflammatory activity to extend the window for BTK inhibition in multiple sclerosis. [PDF]

Ther Adv Neurol Disord
Smolders J, Smets I, Wokke B.
europepmc   +1 more source

Adaptive and Innate Immunity Are Key Drivers of Age at Onset of Multiple Sclerosis. [PDF]

Neurol Genet
Misicka E, Huang Y, Loomis S, Sadhu N, Fisher E, Gafson A, Runz H, Tsai E, Jia X, Herman A, Bronson PG, Bhangale T, Briggs FB.   +12 more
europepmc   +1 more source

The Evolution of Anti-CD20 Treatment for Multiple Sclerosis: Optimization of Antibody Characteristics and Function. [PDF]

CNS Drugs
Cree BAC, Berger JR, Greenberg B.
europepmc   +1 more source

Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability. [PDF]

Drugs
Carlson AK, Amin M, Cohen JA.
europepmc   +1 more source